bluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of “Hold” by Analysts

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have earned an average rating of “Hold” from the twelve ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $5.87.

Several research firms have commented on BLUE. StockNews.com upgraded bluebird bio to a “sell” rating in a research note on Thursday, March 28th. Wedbush dropped their price objective on bluebird bio from $1.72 to $1.68 and set a “neutral” rating on the stock in a research note on Tuesday, March 19th. HSBC dropped their price objective on bluebird bio from $2.31 to $1.02 and set a “reduce” rating on the stock in a research note on Tuesday, March 5th. Royal Bank of Canada reiterated a “sector perform” rating and set a $6.00 price objective on shares of bluebird bio in a research note on Wednesday, March 27th. Finally, Bank of America dropped their price objective on bluebird bio from $12.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, December 21st.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Citigroup Inc. increased its position in shares of bluebird bio by 5.8% in the third quarter. Citigroup Inc. now owns 557,969 shares of the biotechnology company’s stock worth $1,696,000 after purchasing an additional 30,532 shares during the period. Deutsche Bank AG increased its position in shares of bluebird bio by 80.8% in the third quarter. Deutsche Bank AG now owns 692,881 shares of the biotechnology company’s stock worth $2,106,000 after purchasing an additional 309,690 shares during the period. Bleichroeder LP bought a new position in shares of bluebird bio in the third quarter worth $2,736,000. Aigen Investment Management LP bought a new position in shares of bluebird bio in the third quarter worth $34,000. Finally, Vanguard Group Inc. increased its position in shares of bluebird bio by 0.8% in the third quarter. Vanguard Group Inc. now owns 5,617,460 shares of the biotechnology company’s stock worth $17,077,000 after purchasing an additional 46,216 shares during the period. Institutional investors own 87.43% of the company’s stock.

bluebird bio Stock Performance

NASDAQ BLUE opened at $1.03 on Tuesday. The stock has a market capitalization of $112.62 million, a price-to-earnings ratio of -1.39 and a beta of 0.74. The stock’s 50 day moving average price is $1.27 and its two-hundred day moving average price is $2.09. bluebird bio has a 52 week low of $0.88 and a 52 week high of $5.53.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.